Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations

Trial Profile

An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Tolcapone (Primary)
  • Indications Amyloidosis
  • Focus Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 11 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
    • 11 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
    • 12 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top